Literature DB >> 16860874

Prevention of depression in subclinically depressed adults: follow-up effects on the 'Coping with Depression' course.

E Allart-van Dam1, C M H Hosman, C A L Hoogduin, C P D R Schaap.   

Abstract

BACKGROUND: People with subclinical depressive symptoms are at increased risk of depressive disorder, little is known on the prevention of depressive disorder in this population. This study evaluates the long-term preventive effects of an effective depression treatment, the Coping with Depression (CWD) course. This paper describes the effect of the CWD course on the incidence of depressive episodes and depressive symptoms, and explores whether the initial level of symptoms and gender has differential intervention effects.
METHODS: Participants (N=104) were adults with subclinical depressive symptoms, who were randomly assigned to either a preventive group course condition, the 'Coping with Depression' course, or to an assessment-and-advice-only control group condition. Follow-up results were measured 6 and 12 months after completion of the course.
RESULTS: The CWD course showed to be effective in preventing depressive symptomatology but there was no evidence that the course prevented depressive disorder. 25% of the control group and 27.3% of the course group developed a depressive disorder within a year. Initial depressive symptomatology moderated the outcomes: only participants with low initial symptomatology appeared to benefit in the long term from course participation.
CONCLUSIONS: The CWD course is effective as a treatment for subclinical depression. Preventive effects are restricted to participants with initially low depression levels. Therefore, this subgroup should be targeted in future depression-prevention practices and in future prevention studies.

Entities:  

Mesh:

Year:  2006        PMID: 16860874     DOI: 10.1016/j.jad.2006.06.020

Source DB:  PubMed          Journal:  J Affect Disord        ISSN: 0165-0327            Impact factor:   4.839


  14 in total

1.  The treatment of minor depression with St. John's Wort or citalopram: failure to show benefit over placebo.

Authors:  Mark Hyman Rapaport; Andrew A Nierenberg; Robert Howland; Christina Dording; Pamela J Schettler; David Mischoulon
Journal:  J Psychiatr Res       Date:  2011-05-31       Impact factor: 4.791

Review 2.  Preventing the onset of major depressive disorder: a meta-analytic review of psychological interventions.

Authors:  Kim van Zoonen; Claudia Buntrock; David Daniel Ebert; Filip Smit; Charles F Reynolds; Aartjan T F Beekman; Pim Cuijpers
Journal:  Int J Epidemiol       Date:  2014-04       Impact factor: 7.196

3.  Reducing depressive symptoms through behavioral activation in churches: A Hybrid-2 randomized effectiveness-implementation design.

Authors:  Tiffany Haynes; Jerome Turner; Johnny Smith; Geoffrey Curran; Keneshia Bryant-Moore; Songthip T Ounpraseuth; Teresa Kramer; Kimberly Harris; Ellen Hutchins; Karen Hye-Cheon Kim Yeary
Journal:  Contemp Clin Trials       Date:  2017-11-21       Impact factor: 2.226

4.  Feasibility and impact of a guided symptom exposure augmented cognitive behavior therapy protocol to prevent symptoms of pharmacologically induced depression: A pilot study.

Authors:  Lata K McGinn; Anna Van Meter; Ian Kronish; Jessica Gashin; Karen Burns; Natalie Kil; Thomas G McGinn
Journal:  Cognit Ther Res       Date:  2019-02-12

5.  Adaptation of the Cognitive Triad Inventory into Turkish: a Validity and Reliability Study.

Authors:  Özge Erarslan; Sedat Işikli
Journal:  Noro Psikiyatr Ars       Date:  2019-01-31       Impact factor: 1.339

6.  Psychoeducation to facilitate return to work in individuals on sick leave and at risk of having a mental disorder: protocol of a randomised controlled trial.

Authors:  Pernille Pedersen; Hans Jørgen Søgaard; Bjarne Frostholm Yde; Merete Labriola; Ellen A Nohr; Chris Jensen
Journal:  BMC Public Health       Date:  2014-12-17       Impact factor: 3.295

7.  Preventing the onset of major depression based on the level and profile of risk of primary care attendees: protocol of a cluster randomised trial (the predictD-CCRT study).

Authors:  Juan Ángel Bellón; Sonia Conejo-Cerón; Patricia Moreno-Peral; Michael King; Irwin Nazareth; Carlos Martín-Pérez; Carmen Fernández-Alonso; María Isabel Ballesta-Rodríguez; Anna Fernández; José María Aiarzaguena; Carmen Montón-Franco; Inmaculada Ibanez-Casas; Emiliano Rodríguez-Sánchez; Antonina Rodríguez-Bayón; Antoni Serrano-Blanco; María Cruz Gómez; Pilar LaFuente; María Del Mar Muñoz-García; Pilar Mínguez-Gonzalo; Luz Araujo; Diego Palao; Maite Espinosa-Cifuentes; Fernando Zubiaga; Desirée Navas-Campaña; Juan Mendive; Jose Manuel Aranda-Regules; Alberto Rodriguez-Morejón; Luis Salvador-Carulla; Juan de Dios Luna
Journal:  BMC Psychiatry       Date:  2013-06-19       Impact factor: 3.630

8.  Effectiveness of a psycho-educational group program for major depression in primary care: a randomized controlled trial.

Authors:  Rocío Casañas; Rosa Catalán; Jose Luis del Val; Jordi Real; Sergi Valero; Miquel Casas
Journal:  BMC Psychiatry       Date:  2012-12-18       Impact factor: 3.630

9.  Evaluation of the Effectiveness of a Psychoeducational Intervention in Treatment-Naïve Patients with Antidepressant Medication in Primary Care: A Randomized Controlled Trial.

Authors:  R Casañas; R Catalán; R Penadés; J Real; S Valero; Ma Muñoz; Ll Lalucat-Jo; M Casas
Journal:  ScientificWorldJournal       Date:  2015-08-25

10.  Patients' opinions about knowing their risk for depression and what to do about it. The predictD-qualitative study.

Authors:  Juan Á Bellón; Patricia Moreno-Peral; Berta Moreno-Küstner; Emma Motrico; José M Aiarzagüena; Anna Fernández; Carmen Fernández-Alonso; Carmen Montón-Franco; Antonina Rodríguez-Bayón; María Isabel Ballesta-Rodríguez; Ariadne Runte-Geidel; Ariadne Rüntel-Geidel; Janire Payo-Gordón; Antoni Serrano-Blanco; Bárbara Oliván-Blázquez; Luz Araujo; María del Mar Muñoz-García; Michael King; Irwin Nazareth; Manuel Amezcua
Journal:  PLoS One       Date:  2014-03-19       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.